Ventyx Abandons TYK2 Inhibitor Development Following Phase II Failure in Crohn’s Disease

Company and Drug::
Ventyx Biosciences was developing an investigational oral TYK2 inhibitor called VTX958.

Clinical Trial Outcome::
The Phase II clinical trial for VTX958 in Crohn's disease did not meet its primary endpoint, leading to the drug's failure.

Impact on Shares::
The failure of the trial resulted in a significant drop in Ventyx Biosciences' shares, over 20%.

Previous Failures::
This is not the first failure for VTX958; it had previously failed in a Phase II trial for psoriasis.

Development Status::
Ventyx Biosciences has decided to end the development of VTX958 due to these consecutive failures.

Disease Target::
The drug was intended to treat moderately to severely active Crohn's disease.

Announcement Date::
The results were announced on July 29, 2024.